Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Lactobacillus plantarum and Leuconostoc mesenteroides Probiotics on Human Seasonal and Avian Influenza Viruses

  • Bae, Joon-Yong (Department of Microbiology, Institute for Viral Diseases, College of Medicine, Korea University) ;
  • Kim, Jin Il (Department of Microbiology, Institute for Viral Diseases, College of Medicine, Korea University) ;
  • Park, Sehee (Department of Microbiology, Institute for Viral Diseases, College of Medicine, Korea University) ;
  • Yoo, Kirim (Department of Microbiology, Institute for Viral Diseases, College of Medicine, Korea University) ;
  • Kim, In-Ho (Korea Food Research Institute) ;
  • Joo, Wooha (Daesang Co., Ltd.) ;
  • Ryu, Byung Hee (Daesang Co., Ltd.) ;
  • Park, Mee Sook (Department of Microbiology, Institute for Viral Diseases, College of Medicine, Korea University) ;
  • Lee, Ilseob (Department of Microbiology, Institute for Viral Diseases, College of Medicine, Korea University) ;
  • Park, Man-Seong (Department of Microbiology, Institute for Viral Diseases, College of Medicine, Korea University)
  • Received : 2018.04.04
  • Accepted : 2018.04.11
  • Published : 2018.06.28
Download PDF
⟨ Previous Next ⟩

Abstract

Influenza viruses that cause recurrent seasonal epidemics to humans can be controlled with vaccine and antiviral therapy. However, the medical treatments often exhibit limited efficacy in the elderly or immunosuppressed individuals. In these cases, daily uptake of probiotics may be an option to bring in health benefits against influenza. Here, we demonstrate the effects of probiotics Lactobacillus plantarum (Lp) and Leuconostoc mesenteroides (Lm) against seasonal and avian influenza viruses. As assessed by the plaque size reduction of human H1N1 and avian influenza H7N9 viruses, including green fluorescent protein-tagged H1N1 strain in cells, the selected Lp and Lm strains restrained viral replication in mouse lungs with statistical significance. Against lethal viral challenge, the Lp and Lm strains exhibited their beneficial effects by increasing the mean days and rates of survival of the infected mice. These results suggest that, despite rather narrow ranges of protective efficacy, the dietary supplement of Lactobacillus and Leuconostoc probiotics may promote health benefits against influenza.

Keywords

References

  1. Palese P. 2004. Influenza: old and new threats. Nat. Med. 10: S82-S87. https://doi.org/10.1038/nm1141
  2. Neumann G, Kawaoka Y. 2011. The first influenza pandemic of the new millennium. Influenza Other Respir. Viruses 5: 157-166. https://doi.org/10.1111/j.1750-2659.2011.00231.x
  3. Webster RG, Govorkova EA. 2014. Continuing challenges in influenza. Ann. N. Y. Acad. Sci. 1323: 115-139. https://doi.org/10.1111/nyas.12462
  4. Lam TT, Wang J, Shen Y, Zhou B, Duan L, Cheung CL, et al. 2013. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 502: 241-244. https://doi.org/10.1038/nature12515
  5. Wright PF, Neumann G, Kawaoka Y. 2013. Orthomyxoviruses. In Knipe DM, Howley PM (eds.), Fields Virology, 6th Ed. Ch. 41. Lippincott Williams & Wilkins, Philadelphia, USA.
  6. Krammer F, Garcia-Sastre A, Palese P. 2017. Is it possible to develop a "universal" influenza virus vaccine? Toward a universal influenza virus vaccine: potential target antigens and critical aspects for vaccine development. Cold Spring Harb. Perspect. Biol. 2017: a028845.
  7. Hill D, Sugrue I, Arendt E, Hill C, Stanton C, Ross RP. 2017. Recent advances in microbial fermentation for dairy and health. F1000Res. 6: 751. https://doi.org/10.12688/f1000research.10896.1
  8. MacDonald TT, Bell I. 2010. Probiotics and the immune response to vaccines. Proc. Nutr. Soc. 69: 442-446. https://doi.org/10.1017/S0029665110001758
  9. de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, et al. 2006. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine 24: 6670-6674. https://doi.org/10.1016/j.vaccine.2006.05.048
  10. Guillemard E, Tondu F, Lacoin F, Schrezenmeir J. 2010. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 103: 58-68. https://doi.org/10.1017/S0007114509991395
  11. Boge T, Remigy M, Vaudaine S, Tanguy J, Bourdet-Sicard R, van der Werf S. 2009. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine 27: 5677-5684. https://doi.org/10.1016/j.vaccine.2009.06.094
  12. Van Puyenbroeck K, Hens N, Coenen S, Michiels B, Beunckens C, Molenberghs G, et al. 2012. Efficacy of daily intake of Lactobacillus casei Shirota on respiratory symptoms and influenza vaccination immune response: a randomized, double-blind, placebo-controlled trial in healthy elderly nursing home residents. Am. J. Clin. Nutr. 95: 1165-1171. https://doi.org/10.3945/ajcn.111.026831
  13. Pessione E, Cirrincione S. 2016. Bioactive molecules released in food by lactic acid bacteria: encrypted peptides and biogenic amines. Front. Microbiol. 7: 876.
  14. Cho J, Lee D, Yang C, Jeon J, Kim J, Han H. 2006. Microbial population dynamics of kimchi, a fermented cabbage product. FEMS Microbiol. Lett. 257: 262-267. https://doi.org/10.1111/j.1574-6968.2006.00186.x
  15. Jung JY, Lee SH, Jeon CO. 2014. Kimchi microflora: history, current status, and perspectives for industrial kimchi production. Appl. Microbiol. Biotechnol. 98: 2385-2393. https://doi.org/10.1007/s00253-014-5513-1
  16. Choi CY, Kim YH, Oh S, Lee HJ, Kim JH, Park SH, et al. 2017. Anti-inflammatory potential of a heat-killed Lactobacillus strain isolated from kimchi on house dust mite-induced atopic dermatitis in NC/Nga mice. J. Appl. Microbiol. 123: 535-543. https://doi.org/10.1111/jam.13515
  17. Park S, Kim JI, Bae JY, Yoo K, Kim H, Kim IH, et al. 2018. Effects of heat-killed Lactobacillus plantarum against influenza viruses in mice. J. Microbiol. 56: 145-149. https://doi.org/10.1007/s12275-018-7411-1
  18. Lee YD, Hong YF, Jeon B, Jung BJ, Chung DK, Kim H. 2016. Differential cytokine regulatory effect of three Lactobacillus strains isolated from fermented foods. J. Microbiol. Biotechnol. 26: 1517-1526. https://doi.org/10.4014/jmb.1601.01044
  19. Kwak MK, Liu R, Kwon JO, Kim MK, Kim AH, Kang SO. 2013. Cyclic dipeptides from lactic acid bacteria inhibit proliferation of the influenza A virus. J. Microbiol. 51: 836-843. https://doi.org/10.1007/s12275-013-3521-y
  20. Maeda N, Nakamura R, Hirose Y, Murosaki S, Yamamoto Y, Kase T, et al. 2009. Oral administration of heat-killed Lactobacillus plantarum L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. Int. Immunopharmacol. 9: 1122-1125. https://doi.org/10.1016/j.intimp.2009.04.015
  21. Kiso M, Takano R, Sakabe S, Katsura H, Shinya K, Uraki R, et al. 2013. Protective efficacy of orally administered, heatkilled Lactobacillus pentosus b240 against influenza A virus. Sci. Rep. 3: 1563. https://doi.org/10.1038/srep01563
  22. Goto H, Sagitani A, Ashida N, Kato S, Hirota T, Shinoda T, et al. 2013. Anti-influenza virus effects of both live and nonlive Lactobacillus acidophilus L-92 accompanied by the activation of innate immunity. Br. J. Nutr. 110: 1810-1818. https://doi.org/10.1017/S0007114513001104
  23. Kim JI, Lee I, Park S, Park MS. 2012. Surface glycoproteins determine the feature of the 2009 pandemic H1N1 virus. BMB Rep. 45: 653-658. https://doi.org/10.5483/BMBRep.2012.45.11.137
  24. Kim JI, Lee I, Park S, Hwang MW, Bae JY, Lee S, et al. 2013. Genetic requirement for hemagglutinin glycosylation and its implications for influenza A H1N1 virus evolution. J. Virol. 87: 7539-7549. https://doi.org/10.1128/JVI.00373-13
  25. Park S, Kim JI, Lee I, Bae JY, Yoo K, Nam M, et al. 2017. Adaptive mutations of neuraminidase stalk truncation and deglycosylation confer enhanced pathogenicity of influenza A viruses. Sci. Rep. 7: 10928. https://doi.org/10.1038/s41598-017-11348-0
  26. Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, Garcia-Sastre A. 2010. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc. Natl. Acad. Sci. USA 107: 11531-11536. https://doi.org/10.1073/pnas.0914994107
  27. Kim JI, Park S, Lee I, Lee S, Shin S, Won Y, et al. 2012. GFPexpressing influenza A virus for evaluation of the efficacy of antiviral agents. J. Microbiol. 50: 359-362. https://doi.org/10.1007/s12275-012-2163-9
  28. Lee I, Kim JI, Park S, Bae JY, Yoo K, Yun SH, et al. 2017. Single PA mutation as a high yield determinant of avian influenza vaccines. Sci. Rep. 7: 40675. https://doi.org/10.1038/srep40675
  29. Park S, Kim JI, Lee I, Lee S, Hwang MW, Bae JY, et al. 2013. Aronia melanocarpa and its components demonstrate antiviral activity against influenza viruses. Biochem. Biophys. Res. Commun. 440: 14-19. https://doi.org/10.1016/j.bbrc.2013.08.090
  30. Centers for Disease Control and Prevention (CDC). 2018. Disease burden of influenza. Available at https://www.cdc.gov/flu/about/disease/burden.htm.Accessed March 16, 2018.
  31. World Health Organization (WHO). 2018. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. Available at http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/. Accessed March 2, 2018.
  32. Food and Agriculture Organization of the United Nations (FAO). 2018. H7N9 situation. Available at http://www.fao.org/ag/againfo/programmes/en/empres/H7N9/situation_ update.html). Accessed March 28, 2018.
  33. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, et al. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 60: 1-24.
  34. Centers for Disease Control and Prevention (CDC). 2018. Seasonal influenza vaccine effectiveness, 2005-2018. Available at https://www.cdc.gov/flu/professionals/vaccination/ effectiveness-studies.htm). Accessed March 15, 2018.
  35. Nachbagauer R, Krammer F. 2017. Universal influenza virus vaccines and therapeutic antibodies. Clin. Microbiol. Infect. 23: 222-228. https://doi.org/10.1016/j.cmi.2017.02.009
  36. Harding AT, Heaton NS. 2018. Efforts to improve the seasonal influenza vaccine. Vaccines (Basel) 6: E19. https://doi.org/10.3390/vaccines6020019
  37. Naesens L, Stevaert A, Vanderlinden E. 2016. Antiviral therapies on the horizon for influenza. Curr. Opin. Pharmacol. 30: 106-115. https://doi.org/10.1016/j.coph.2016.08.003
  38. Park S, Kim JI, Park MS. 2012. Antiviral agents against influenza viruses. J. Bacteriol. Virol. 42: 284-293. https://doi.org/10.4167/jbv.2012.42.4.284
  39. Zimmermann P, Curtis N. 2018. The influence of probiotics on vaccine responses - a systematic review. Vaccine 36: 207-213. https://doi.org/10.1016/j.vaccine.2017.08.069
  40. Vitetta L, Saltzman ET, Thomsen M, Nikov T, Hall S. 2017. Adjuvant probiotics and the intestinal microbiome: enhancing vaccines and immunotherapy outcomes. Vaccines (Basel) 5: 50. https://doi.org/10.3390/vaccines5040050
  41. Chen MF, Weng KF, Huang SY, Liu YC, Tseng SN, Ojcius DM, et al. 2017. Pretreatment with a heat-killed probiotic modulates monocyte chemoattractant protein-1 and reduces the pathogenicity of influenza and enterovirus 71 infections. Mucosal Immunol. 10: 215-227. https://doi.org/10.1038/mi.2016.31
  42. Starosila D, Rybalko S, Varbanetz L, Ivanskaya N, Sorokulova I. 2017. Anti-influenza activity of a Bacillus subtilis probiotic strain. Antimicrob. Agents Chemother. 61: e00539-17.
  43. Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas RE, et al. 2018. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev. 2: CD004876.
  44. Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. 2018. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst. Rev. 2: CD008983.
  45. Yeh TL, Shih PC, Liu SJ, Lin CH, Liu JM, Lei WT, et al. 2018. The influence of prebiotic or probiotic supplementation on antibody titers after influenza vaccination: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel. Ther. 12: 217-230. https://doi.org/10.2147/DDDT.S155110
  46. Jung YJ, Lee YT, Ngo VL, Cho YH, Ko EJ, Hong SM, et al. 2017. Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection. Sci. Rep. 7: 17360. https://doi.org/10.1038/s41598-017-17487-8
  47. Lei WT, Shih PC, Liu SJ, Lin CY, Yeh TL. 2017. Effect of probiotics and prebiotics on immune response to influenza vaccination in adults: a systematic review and meta-analysis of randomized controlled trials. Nutrients 9: 1175. https://doi.org/10.3390/nu9111175
  48. Palese P, Tobita K, Ueda M, Compans RW. 1974. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61: 397-410. https://doi.org/10.1016/0042-6822(74)90276-1

Cited by

  1. Bioactive Compound Prodigiosin in Vivo Affecting the Nutrient Metabolism of Weaned Rats vol.3, pp.12, 2018, https://doi.org/10.1021/acsomega.8b02476
  2. Antioxidant properties of Angelica dahurica extracts fermented by probiotics strains isolated from gimchi vol.35, pp.4, 2018, https://doi.org/10.12925/jkocs.2018.35.4.1276
  3. Short Communication: Oral Administration of Heat-killed Lactobacillus brevis KB290 in Combination with Retinoic Acid Provides Protection against Influenza Virus Infection in Mice vol.12, pp.10, 2018, https://doi.org/10.3390/nu12102925
  4. The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment? vol.148, pp.None, 2018, https://doi.org/10.1016/j.micpath.2020.104452
  5. Akkermansia muciniphila Improves Host Defense Against Influenza Virus Infection vol.11, pp.None, 2018, https://doi.org/10.3389/fmicb.2020.586476